GANX

NASD Gain Therapeutics, Inc.
Oct 2, 2026 · 12:08 PM ET DELAYED Market Open

$1.74 ↑ +0.02 (+0.87%) Trading Up from the previous close of $1.72, $0.04 below the day’s high of $1.78

YTD change
-46.12%
vs 20-day SMA
-2.23%
vs 200-day SMA
-14.23%

Price ranges

Previous day
$1.67 $1.77
open $1.74 close $1.72
-$0.02 (-1.15%)
Today
$1.71 $1.78
open $1.75 now $1.74
-$0.01 (-0.86%)
Past week
$1.60 $1.88
from $1.84 now $1.74
-$0.11 (-5.71%)
Past month
$1.60 $1.97
from $1.79 now $1.74
-$0.05 (-3.07%)
This year
$1.53 $3.29
from $3.22 now $1.74
-$1.49 (-46.12%)

Price & Performance

-0.13 (-7.03%) / 6M

$1.54$1.77$1.99$2.21Apr 2Jul 2Oct 1

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 90.3% away from all-time highs of $17.93
  • GANX is down 46% since the beginning of the year
  • GANX is down 7% over the past 12 months
  • GANX is down 3% over the past 1 month
  • 7% of all GANX investors are betting against GANX

GANX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -7.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.11
Earnings momentum +11.3% Quarterly EPS growth
Quarterly change +11.3%

Valuation

P/E ratio N/A
Enterprise value $61.3M
Beta -0.46

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$13.1M
Debt$610.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $74.0M

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $407.27 -3.38%
MRNA Moderna, Inc. $188.94 -1.89%
RVMD Revolution Medicines, Inc. $205.89 +0.31%
ROIV Roivant Sciences Ltd. $35.50 -2.93%
BNTX BioNTech SE Sponsored ADR $96.85 -1.48%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.